Pfizer Inc holds a concentrated book of 21 stocks worth $437.5M as of Q3 2025 (disclosed Nov 13, 2025, a ~44-day 13F lag). This quarter they opened Nextcure Inc and trimmed Biontech SE-ADR. Their largest long position is Biontech SE-ADR at 37% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
86% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Pfizer Inc
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 19 / 21 | $943.9M |
| MORGAN STANLEY | 19 / 21 | $448.2M |
| UBS Group AG | 19 / 21 | $87.7M |
| SBI Securities Co., Ltd. | 19 / 21 | $1.0M |
| GEODE CAPITAL MANAGEMENT, LLC | 18 / 21 | $293.8M |
| Ken Griffin | 18 / 21 | $206.4M |
| BNP PARIBAS FINANCIAL MARKETS | 18 / 21 | $187.0M |
| STATE STREET CORP | 17 / 21 | $493.9M |
Ranked by how many of Pfizer Inc's top 21 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Biontech SE SPONSORED ADS | $163.5M | 1.66M | 37.4% | ▼−55% Reduced · −2.0M sh | |
| 2 | Oric Pharmaceuticals Inc COM | $64.5M | 5.38M | 14.7% | —Held | |
| 3 | Tourmaline Bio Inc COM | $60.8M | 1.27M | 13.9% | —Held | |
| 4 | Arvinas Inc COM | $29.5M | 3.46M | 6.7% | —Held | |
| 5 | Allogene Therapeutics Inc COM | $27.3M | 22.03M | 6.2% | —Held | |
| 6 | Celcuity Inc COM | $17.3M | 349.4K | 3.9% | —Held | |
| 7 | Pyxis Oncology Inc COMMON STOCK | $15.6M | 7.03M | 3.6% | —Held | |
| 8 | Wave Life Sciences Ltd SHS | $13.7M | 1.88M | 3.1% | —Held | |
| 9 | Zura Bio Ltd CLASS A ORD SHS | $12.9M | 2.97M | 2.9% | —Held | |
| 10 | Caribou Biosciences Inc COM | $10.9M | 4.69M | 2.5% | —Held | |
| 11 | Biohaven Ltd COM | $7.6M | 505.6K | 1.7% | —Held | |
| 12 | Cardiff Oncology Inc COM | $5.0M | 2.41M | 1.1% | —Held | |
| 13 | Spero Therapeutics Inc COM | $4.4M | 2.36M | 1.0% | —Held | |
| 14 | Zentalis Pharmaceuticals Inc COM | $1.4M | 953.8K | 0.3% | —Held | |
| 15 | Nextcure Inc COM NEW | $924K | 157.6K | 0.2% | ▲New New position | |
| 16 | An2 Therapeutics Inc COM | $908K | 715.3K | 0.2% | —Held | |
| 17 | Q32 Bio Inc COM | $550K | 277.8K | 0.1% | —Held | |
| 18 | Essa Pharma Inc COM NEW | $320K | 1.68M | 0.1% | —Held | |
| 19 | Bolt Biotherapeutics Inc COM NEW | $167K | 31.3K | 0.0% | —Held | |
| 20 | Ginkgo Bioworks Holdings Inc CL A NEW | $43K | 2.9K | 0.0% | —Held | |
| 21 | Senseonics Hldgs Inc COM | $19K | 43.4K | 0.0% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/78003/holdings"
Use Arkolith to show PFIZER INC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.